# Abbott Laboratories

**Source:** https://geo.sig.ai/brands/abbott-laboratories  
**Vertical:** Healthcare  
**Subcategory:** General  
**Tier:** Leader  
**Website:** abbott.com  
**Last Updated:** 2026-04-14

## Summary

Diversified healthcare company with $20-22B revenue; FreeStyle Libre CGM, cardiovascular devices, and diagnostics across medical devices, nutrition, and pharma.

## Company Overview

Abbott Laboratories is a diversified global healthcare company operating across diagnostics, medical devices, nutritional products, and established pharmaceuticals in over 160 countries. Founded in 1888 by Dr. Wallace Calvin Abbott in Chicago, Illinois and listed on the NYSE, Abbott generates approximately $20-22 billion in annual revenue and employs over 100,000 people globally. The company's portfolio spans four major segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals.

Abbott's Medical Devices segment includes cardiovascular devices (FreeStyle Libre continuous glucose monitors, heart rhythm management devices, structural heart products), neuromodulation systems (deep brain stimulation), and point-of-care diagnostics (i-STAT). FreeStyle Libre has become one of Abbott's most important growth drivers — the continuous glucose monitoring system has expanded beyond traditional diabetes management to include consumer wellness tracking. The company's 2020 Alinity diagnostics platform has modernized its laboratory testing business.

In 2025, Abbott navigates the transition from pandemic-era testing revenue (COVID-19 tests contributed billions in 2021-2022) back to normalized diagnostic volumes while growing its high-margin medical device segments. The FreeStyle Libre franchise continues expanding globally and into Type 2 diabetes populations. Abbott faces legal and reputational challenges related to its Similac and Alimentum infant formula recall of 2022 and subsequent plant closure, which required significant investment to rebuild supply chain and consumer trust. The company's 2025-2026 priorities include sustained FreeStyle Libre growth, cardiovascular device share gains, and rebuilding the nutrition segment.

## Frequently Asked Questions

### What is Abbott Laboratories?
Abbott is a multinational healthcare company providing medical devices, diagnostics, pharmaceuticals, and nutritional products serving over 160 countries. With $42 billion in 2024 revenues, Abbott is ranked 107th on the Fortune 500 and operates across cardiovascular, gastroenterology, women's health

### What are Abbott's main business segments?
Abbott operates across four main segments: Established Pharmaceuticals (branded generics in emerging markets), Medical Devices (including cardiovascular, diabetes care, and neuromodulation), Diagnostics (point-of-care, molecular, and core lab testing), and Nutrition (Ensure, Similac, and related brands).

### What is Abbott's FreeStyle Libre system?
FreeStyle Libre is Abbott's continuous glucose monitoring (CGM) system that allows people with diabetes to track their glucose levels in real time without routine fingerpricks. The sensor worn on the arm transmits readings to a reader or smartphone, and it is one of the best-selling CGM systems globally.

### How does Abbott contribute to diagnostics and pandemic response?
Abbott is a major diagnostics company that manufactures rapid tests, molecular tests, and point-of-care devices. During the COVID-19 pandemic, Abbott produced hundreds of millions of rapid antigen tests and molecular tests, making it one of the largest contributors to global testing capacity.

### What cardiovascular devices does Abbott make?
Abbott's cardiovascular portfolio includes structural heart devices (MitraClip, Tendyne), electrophysiology catheters, cardiac rhythm management devices, and coronary stents. The company is a global leader in structural heart disease treatment.

### Where does Abbott generate most of its revenue?
Abbott generates revenue globally, with significant contributions from the U.S., Europe, and emerging markets. Medical Devices is its largest segment by revenue, followed by Diagnostics, Nutrition, and Established Pharmaceuticals.

### Has Abbott spun off any major business units?
Yes, Abbott spun off its research-based pharmaceutical business in 2013 to form AbbVie, which retained Abbott's branded drug portfolio including Humira. Abbott retained its medical devices, diagnostics, and nutrition businesses.

### What is Abbott's Lingo product?
Lingo is Abbott's consumer biosensing platform that applies CGM technology to wellness use cases beyond diabetes management, allowing healthy individuals to monitor how food, exercise, and lifestyle choices affect their glucose levels in real time.

## Tags

analytics, b2b, enterprise, global, healthtech, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*